Clinical trials: Neuropathy, Painful
Pain, Diabetic Neuropathies
Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy
The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients with painful diabetic neuropathy.
- Trial name
- NCT01347671
- Testing
- GRT6005
- Where
- 22 sites in Bulgaria, Germany and 1 more
- Volunteers
- 189 people
- Sponsor
- Tris Pharma, Inc.
Diabetic Neuropathy, Painful
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if…
- Trial name
- NCT00159679
- Testing
- Pregabalin
- Where
- 30 sites in United States
- Volunteers
- 167 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Painful Diabetic Neuropathy
A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)
The purpose of this study is to determine if analgesic efficacy can be detected with single dose administration in patients with chronic neuropathic pain due to painful diabetic neuropathy.
- Trial name
- NCT00837941
- Testing
- Comparator: A: Pregabalin, Comparator: B: Duloxetine, Comparator: C: Diphenhydramine hydrochloride
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Peripheral Neuropathy
IMX-150 Cream for Diabetic Neuropathy
The purpose of this study is to compare the effectiveness of two different dose of IMX-150 to that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the feet.
- Trial name
- NCT00641953
- Testing
- IMX-150
- Where
- 7 sites in United States
- Volunteers
- 155 people
- Sponsor
- Procris Pharmaceuticals
Diabetic Neuralgia, Diabetic Neuropathies
Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD).
- Conditions
- Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
- Trial name
- NCT00507936
- Testing
- ABT-894, Duloxetine
- Where
- 49 sites in United States, Canada and 5 more
- Volunteers
- 280 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Neuropathy, Neuropathy;Peripheral
Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic…
- Trial name
- NCT06912646
- Testing
- Erchonia® EVRL™
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Erchonia Corporation
Lumbosacral Radicular Pain, Sciatic Radiculopathy
Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
The purpose of this study is to evaluate the safety and tolerability of C-1101 administered as a single dose, transforaminal epidural injection compared to sterile saline
- Conditions
- Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain, Sciatica
- Trial name
- NCT07264270
- Testing
- C-1101
- Where
- 6 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Consano Bio
Painful Diabetic Neuropathy
An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy
The primary objective of the trial is to assess the tolerability and safety of long-term SPM 927 administration in subjects with diabetic neuropathy.
- Trial name
- NCT00861042
- Testing
- SPM927/Lacosamide
- Volunteers
- 69 people
- Sponsor
- UCB Pharma
Neuropathic Pain, Distal Sensory Polyneuropathy
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.
- Trial name
- NCT06568042
- Testing
- LY3848575
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Low Back Pain, Migraine
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
- Conditions
- Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
- Trial name
- NCT00228605
- Testing
- OraVescent Fentanyl
- Where
- 38 sites in United States
- Volunteers
- 500 people
- Sponsor
- Cephalon
Lumbar Radiculopathy
Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain
This is a Phase I/II, double-blind, parallel-group, randomized, placebo-controlled multi-centre trial in 180 patients randomized 1:1:1 to receive the IMP (Dexamethasone acetate microspheres for extended-release injectable…
- Trial name
- SALIENT (NCT03952377)
- Testing
- SX600
- Where
- 10 sites in Australia
- Volunteers
- 56 people
- Sponsor
- SpineThera Australia PTY LTD
Diabetes Mellitus, Diabetic Neuropathy, Painful
Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy
EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor.
- Trial name
- NCT00073034
- Testing
- EAA-090
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetic Peripheral Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
The aim of this study is to investigate the pharmacological treatment pattern among patients with diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) in China.
- Conditions
- Diabetic Peripheral Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy, Neuropathic Pain
- Trial name
- NCT06546202
- Testing
- No Drug
- Where
- 10 sites in China
- Volunteers
- 1,271 people
- Sponsor
- Daiichi Sankyo
Post Herpetic Neuralgia, Diabetic Peripheral Neuropathy
Titration Study of ABX-1431
This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs).
- Conditions
- Post Herpetic Neuralgia, Diabetic Peripheral Neuropathy, Small Fiber Neuropathy, Post-Traumatic Neuralgia
- Trial name
- NCT03447756
- Testing
- ABX-1431
- Where
- Moldova
- Volunteers
- 39 people
- Sponsor
- Abide Therapeutics
Diabetic Neuropathies
Study of DA-9801 to Treat Diabetic Neuropathic Pain
This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in the treatment of pain associated with diabetic neuropathy.
- Trial name
- NCT01813799
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetic Peripheral Neuropathy, Pain
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
The purpose of the study is to assess efficacy and safety of a single treatment of Capsaicin 8% transdermal delivery system in reducing pain from damaged nerves (neuropathic pain) caused by diabetes.
- Trial name
- STEP (NCT01533428)
- Testing
- Capsaicin 8%
- Where
- 29 sites in United States
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Diabetic Neuropathy, Painful
PDN Post Market, Multicenter, Prospective, Global Clinical Study
The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN).
- Trial name
- PDN-PM (NCT05301816)
- Testing
- Spinal Cord Stimulator (SCS)
- Where
- 8 sites in United States
- Volunteers
- 497 people
- Sponsor
- Nevro Corp
Diabetic Neuropathies, Pain
The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy
This study is intended to demonstrate that exposure to a high intensity, DC electromagnetic field, as supplied by the investigational device known as the Molecular Magnetic Energizer (MME), will create a clinically meaningful…
- Conditions
- Diabetic Neuropathies, Pain, Neuralgia
- Trial name
- NCT00134524
- Testing
- MME procedure
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Advanced Magnetic Research Institute International
Diabetic Neuropathies
An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics
The purpose of this study is to evaluate the safety, tolerability, and efficacy of carisbamate (800 and 1200 mg/day) in patients with diabetic neuropathic pain.
- Trial name
- NCT00870454
- Testing
- Pregabalin 300 mg/d, Carisbamate 800 mg/d, Carisbamate 1,200 mg/d
- Volunteers
- 386 people
- Sponsor
- SK Life Science, Inc.